HOXB5 and central nervous system cancer: In our study, we certified that HOXB5 was overexpressed in clinical glioma specimens and patient-derived primary GSCs, and the higher expression of HOXB5 correlated with a poorer prognosis in glioma patients, as confirmed by qRT-PCR, western blotting, and Kaplan–Meier survival analyses.